Bio-Techne Corporation
TECH

$11.96 B
Marketcap
$75.27
Share price
Country
$-0.97
Change (1 day)
$85.57
Year High
$61.16
Year Low
Categories

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

marketcap

P/S ratio for Bio-Techne Corporation (TECH)

P/S ratio as of 2024: 9.74

According to Bio-Techne Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 9.74. At the end of 2023 the company had a P/S ratio of 11.29.

P/S ratio history for Bio-Techne Corporation from 1989 to 2024

P/S ratio at the end of each year

Year P/S ratio
2024 9.74
2023 11.29
2022 12.30
2021 18.74
2020 13.66
2019 11.07
2018 8.62
2017 7.79
2016 8.40
2015 8.08
2014 9.54
2013 8.26
2012 8.71
2011 10.67
2010 7.95
2009 9.14
2008 11.77
2007 10.09
2006 9.81
2005 10.37
2004 11.06
2003 8.66
2002 8.83
2001 11.68
2000 25.43
1999 5.61
1998 5.36
1997 4.67
1996 5.38
1995 2.69
1994 2.37
1993 4.71
1992 3.36
1991 2.80
1990 1.39
1989 0.83